While the clinical research industry has taken steps toward more diversity, equity, and inclusion (DEI) within research and development, the gains should be taken in the context of the systemic barriers that remain. Despite stakeholders becoming more intentional and determined about trial diversity and FDA guidance to make trials more representative, there is more to be done to put R&D to work for everyone.
How can stakeholders work toward a more equitable future for R&D?
A new industry trend report indicates they’ll need to upend many legacy processes—such as trying out new sites, reevaluating inclusion criteria, and reaching people in more places. Download the report to explore progress, barriers, and opportunities across patient-centric diversity efforts. Topics include: